{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T15:52:25Z","timestamp":1691769145694},"reference-count":35,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2021,1]]},"abstract":"\nAim and Objective :<\/jats:title>\nThe excessive consumption of alcohol and the installation of\ndependence is, in most cases, facilitated by favorable psychological factors that trigger and\nmaintain the behavior of consumers. Examples more frequently encountered in individuals having\ndifficulty with alcohol are, in particular: one or more anxiety disorders, deficits in the capacities to\nmanage stress and anxiety. The main objective of this work was to study in vivo the anti-addiction\neffect and hepatotoxicity of tow baclofen analogues complexed with \u03b2-Cyclodextrin (\u03b2CD) on an\nalcohol-dependent rat model.<\/jats:p>\n<\/jats:sec>\n\nMaterials and Methods:<\/jats:title>\nThe synthesis of two analogues, ABF1 and ABF2, close to baclofen was\nreported. The structural determination of the two compounds was confirmed by NMR and IR\nanalysis. The complexation of analogues with \u03b2-Cyclodextrin (\u03b2CD) was performed in water at\nroom temperature (25 \u00b0C). The interactions of ABF with \u03b2-Cyclodextrin, and the stability constant\n(Ka) of the inclusion complex formed between them were investigated by using UV-visible\nspectroscopy. The biological effects of baclofen and the two analogues on alcohol dependence\nwere studied in wistar rats. The anti-addiction effect of the analogues was tested by measuring the\nalcohol intake and the variation of the animal behaviour. The toxicity of the compounds was also\nanalysed on liver injury markers.<\/jats:p>\n<\/jats:sec>\n\nResults:<\/jats:title>\nThe amino-3-phenylbutanoic acid (ABF1) and 3,4,5-trihydroxy-N-(methyl-2-acetate)\nbenzamide (ABF2) were synthesized. The complexation of both analogues of baclofen (BF) with\n\u03b2-cyclodextrin (\u03b2CD) (ABF- \u03b2CD) was realized and confirmed by the stability constant of the\ninclusion complex (Ka) and Job\u2019s method. The evaluation of anti-addiction activity in vivo showed\nthat ABF1-\u03b2CD inhibits the consumption of alcohol at doses equivalent to those of baclofen. Both\nbaclofen analogues have shown an anxiolytic effect. Regarding the toxicity of the two compounds,\nour results showed that ABF1-\u03b2CD has less toxic effect than baclofen; it reduces the activity of\nALT and AST enzymes. Histologically, ABF1-\u03b2CD has no effect on the liver structure and has a\nprotective effect against lesions alcohol-induced liver disease.<\/jats:p>\n<\/jats:sec>\n\nConclusion:<\/jats:title>\nTherefore, it can be suggested that ABF1 analogue combined with \u03b2-Cyclodextrin can\nbe used as a treatment for alcohol dependence. Further clinical works are needed to confirm its\neffectiveness.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207323666201209093240","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T04:44:11Z","timestamp":1607575451000},"page":"187-196","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synthesis and Biological Analysis of Anti-addiction Effect and Hepatotoxicity of Tow Baclofen Analogues Complexed with \u03b2-Cyclodextrin"],"prefix":"10.2174","volume":"25","author":[{"given":"Assia","family":"Keniche","sequence":"first","affiliation":[{"name":"Laboratoire de Chimie Organique, Substances Naturelles et Analyses (COSNA), Universite de Tlemcen, BP 119, 13000,Algeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibtissem","family":"EL Ouar","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular and Molecular Immunology, faculty of Life and Natural Sciences, University Fr\u00e8res Mentouri Constantine 1, Constantine,Algeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibtissem","family":"Zeghina","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular and Molecular Immunology, faculty of Life and Natural Sciences, University Fr\u00e8res Mentouri Constantine 1, Constantine,Algeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed El Amine","family":"Dib","sequence":"additional","affiliation":[{"name":"Laboratoire des Substances Naturelles et Bioactives (LASNABIO), Universite de Tlemcen, Tlemcen,Algeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.4.5778.15","volume":"4","author":"Hudgson P.","year":"1971","unstructured":"Hudgson P.; Weightman D.; Baclofen in the treatment of spasticity. BMJ 1971,4(5778),15-17","journal-title":"BMJ"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1021\/jm00017a016","volume":"38","author":"Froestl W.","year":"1995","unstructured":"Froestl W.; Mickel S.J.; von Sprecher G.; Diel P.J.; Hall R.G.; Maier L.; Strub D.; Melillo V.; Baumann P.A.; Bernasconi R.; Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. J Med Chem 1995,38(17),3313-3331","journal-title":"J Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/157488912800673137","volume":"7","author":"Agabio R.","year":"2012","unstructured":"Agabio R.; Maccioni P.; Carai M.A.; Gessa G.L.; Froestl W.; Colombo G.; The development of medications for alcohol-use disorders targeting the GABAB receptor system. Recent Patents CNS Drug Discov 2012,7(2),113-128","journal-title":"Recent Patents CNS Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.12740\/PP\/33911","volume":"49","author":"Agabio R.","year":"2015","unstructured":"Agabio R.; Colombo G.; [GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators] Psychiatr Pol 2015,49(2),215-223","journal-title":"Psychiatr Pol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fnins.2014.00140","volume":"8","author":"Agabio R.","year":"2014","unstructured":"Agabio R.; Colombo G.; GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Front Neurosci 2014,8(140),140","journal-title":"Front Neurosci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/alcalc\/agh130","volume":"40","author":"Ameisen O.","year":"2005","unstructured":"Ameisen O.; Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 2005,40(2),147-150","journal-title":"Alcohol Alcohol"},{"key":"ref=7","author":"Ameisen O.","year":"2008","unstructured":"Ameisen O.; Le Dernier Verre Paris: Denoël, English Edition: The end of my addiction 2008","journal-title":"Le Dernier Verre Paris: Denoël, English Edition: The end of my addiction"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3389\/fpsyt.2018.00506","volume":"9","author":"de Beaurepaire R.","year":"2018","unstructured":"de Beaurepaire R.; A review of the potential mechanisms of action of baclofen in alcohol use disorder. Front Psychiatry 2018,9(506),506","journal-title":"Front Psychiatry"},{"key":"ref=9","first-page":"139","volume":"8","author":"Attia M.","year":"2012","unstructured":"Attia M.; Herdeis C.; Bräuner-Osborne H.; Synthesis and pharmacological characterization of certain baclofen analogues. Dig J Nanomater Biostruct 2012,8(1),139-149","journal-title":"Dig J Nanomater Biostruct"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1023\/A:1015812725011","volume":"8","author":"van Bree J.B.","year":"1991","unstructured":"van Bree J.B.; Heijligers-Feijen C.D.; de Boer A.G.; Danhof M.; Breimer D.D.; Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. Pharm Res 1991,8(2),259-262","journal-title":"Pharm Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1023\/A:1016263032765","volume":"12","author":"Deguchi Y.","year":"1995","unstructured":"Deguchi Y.; Inabe K.; Tomiyasu K.; Nozawa K.; Yamada S.; Kimura R.; Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. Pharm Res 1995,12(12),1838-1844","journal-title":"Pharm Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15406\/ijcam.2017.09.00312","volume":"9","author":"Keniche A.","year":"2017","unstructured":"Keniche A.; Keniche N.; Si Said M.A.; Malti I.; Kajima Mulengi J.; Baclofen as anti-craving agent against several addiction. Int J Complement Alt Med 2017,9(5),1-6","journal-title":"Int J Complement Alt Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"13022","DOI":"10.3390\/ijms140713022","volume":"14","author":"Iacovino R.","year":"2013","unstructured":"Iacovino R.; Rapuano F.; Caso J.V.; Russo A.; Lavorgna M.; Russo C.; Isidori M.; Russo L.; Malgieri G.; Isernia C.; β-Cyclodextrin inclusion complex to improve physicochemical properties of pipemidic acid: characterization and bioactivity evaluation. Int J Mol Sci 2013,14(7),13022-13041","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioelechem.2020.107587","volume":"136","author":"Krzak A.","year":"2020","unstructured":"Krzak A.; Bilewicz R.; Voltammetric\/UV-Vis study of temozolomide inclusion complexes with cyclodextrin derivatives. Bioelectrochemistry 2020,136(7)","journal-title":"Bioelectrochemistry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.13171\/mjc.2.5.2013.01.12.23","volume":"2","author":"Keniche A.","year":"2014","unstructured":"Keniche A.; Slimani M.Z.; José Miranda I.; Jesus Azipura M.; Kajima Mulengi J.; NMR Investigation of the complexation of (S)-2-isopropyl-1-(o-cyclodextrinβnitrophenyl) sulfonyl) aziridine with β-cyclodextrin. Mediterr J Chem 2014,2(5),620-631","journal-title":"Mediterr J Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/10717544.2020.1724210","volume":"27","author":"Ding Y.","year":"2020","unstructured":"Ding Y.; Pang Y.; Vara Prasad C.V.N.S.; Wang B.; Wang B.; Formation of inclusion complex of enrofloxacin with 2-hydroxypropyl-β-cyclodextrin. Drug Deliv 2020,27(1),334-343","journal-title":"Drug Deliv"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ddr.21452","volume":"79","author":"Jacob S.","year":"2018","unstructured":"Jacob S.; Nair A.B.; Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev Res 2018,79(5),201-217","journal-title":"Drug Dev Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"E329","DOI":"10.1208\/pt060243","volume":"6","author":"Challa R.","year":"2005","unstructured":"Challa R.; Ahuja A.; Ali J.; Khar R.K.; Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 2005,6(2),E329-E357","journal-title":"AAPS PharmSciTech"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/ja044370p","volume":"127","author":"Okino T.","year":"2005","unstructured":"Okino T.; Hoashi Y.; Furukawa T.; Xu X.; Takemoto Y.; Enantio- and diastereoselective Michael reaction of 1,3-dicarbonyl compounds to nitroolefins catalyzed by a bifunctional thiourea. J Am Chem Soc 2005,127(1),119-125","journal-title":"J Am Chem Soc"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1021\/ja01176a030","volume":"71","author":"Benesi H.A.","year":"1949","unstructured":"Benesi H.A.; Hildebrand J.H.; A spectrophotometric investigation of the interaction of iodine with aromatic hydrocarbons. J Am Chem Soc 1949,71,2703-2707","journal-title":"J Am Chem Soc"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1590\/1516-4446-2013-1149","volume":"35","author":"Planeta C.S.","year":"2013","unstructured":"Planeta C.S.; Animal models of alcohol and drug dependence. Br J Psychiatry 2013,35(2),140-146","journal-title":"Br J Psychiatry"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bbr.2005.12.001","volume":"169","author":"Brenes Sáenz J.C.","year":"2006","unstructured":"Brenes Sáenz J.C.; Villagra O.R.; Fornaguera Trías J.; Factor analysis of Forced Swimming test, Sucrose Preference test and Open Field test on enriched, social and isolated reared rats. Behav Brain Res 2006,169(1),57-65","journal-title":"Behav Brain Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.13070\/mm.en.2.122","volume":"2","author":"Teegarden S.","year":"2012","unstructured":"Teegarden S.; Behavioral phenotyping in rats and mice. Mater Methods 2012,2,122","journal-title":"Mater Methods"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jpba.2005.05.011","volume":"39","author":"Li N.","year":"2005","unstructured":"Li N.; Zhang Y.H.; Wu Y.N.; Xiong X-L.; Zhang Y.H.; Inclusion complex of trimethoprim with β-cyclodextrin. J Pharm Biomed Anal 2005,39(3-4),824-829","journal-title":"J Pharm Biomed Anal"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/10610270802596403","volume":"21","author":"Zhanga M.","year":"2009","unstructured":"Zhanga M.; Lib J.; Jiaa W.; Chaob J.; Zhang L.; Theoretical and experimental study of the inclusion complexes of ferulic acid with cyclodextrin. Supramol Chem 2009,21(7),597-602","journal-title":"Supramol Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0076-6879(82)87029-8","volume":"87","author":"Huang C.Y.","year":"1982","unstructured":"Huang C.Y.; Determination of binding stoichiometry by the continuous variation method: the Job plot. Methods Enzymol 1982,87,509-525","journal-title":"Methods Enzymol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/npp.2013.138","volume":"38","author":"Ozburn A.R.","year":"2013","unstructured":"Ozburn A.R.; Falcon E.; Mukherjee S.; Gillman A.; Arey R.; Spencer S.; McClung C.A.; The role of clock in ethanol-related behaviors. Neuropsychopharmacology 2013,38(12),2393-2400","journal-title":"Neuropsychopharmacology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrn.2016.85","volume":"17","author":"Ron D.","year":"2016","unstructured":"Ron D.; Barak S.; Molecular mechanisms underlying alcohol-drinking behaviours. Nat Rev Neurosci 2016,17(9),576-591","journal-title":"Nat Rev Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/BF03033315","volume":"6","author":"Colombo G.","year":"2004","unstructured":"Colombo G.; Addolorato G.; Agabio R.; Carai M.A.M.; Pibiri F.; Serra S.; Vacca G.; Gessa G.L.; Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res 2004,6(5),403-414","journal-title":"Neurotox Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","volume":"463","author":"Prut L.","year":"2003","unstructured":"Prut L.; Belzung C.; The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review. Eur J Pharmacol 2003,463(1-3),3-33","journal-title":"Eur J Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0014-2999(03)01274-3","volume":"463","author":"Bourin M.","year":"2003","unstructured":"Bourin M.; Hascoët M.; The mouse light\/dark box test. Eur J Pharmacol 2003,463(1-3),55-65","journal-title":"Eur J Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00261-018-1465-8","volume":"43","author":"Brancatelli G.","year":"2018","unstructured":"Brancatelli G.; Furlan A.; Calandra A.; Dioguardi Burgio M.; Hepatic sinusoidal dilatation. Abdom Radiol (NY) 2018,43(8),2011-2022","journal-title":"Abdom Radiol (NY)"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1053\/j.ajkd.2017.07.005","volume":"71","author":"Wolf E.","year":"2018","unstructured":"Wolf E.; Kothari N.R.; Roberts J.K.; Sparks M.A.; Baclofen toxicity in kidney disease. Am J Kidney Dis 2018,71(2),275-280","journal-title":"Am J Kidney Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"E157","DOI":"10.1152\/ajpendo.00615.2006","volume":"294","author":"Bonaventura M.M.","year":"2008","unstructured":"Bonaventura M.M.; Catalano P.N.; Chamson-Reig A.; Arany E.; Hill D.; Bettler B.; Saravia F.; Libertun C.; Lux-Lantos V.A.; GABAB receptors and glucose homeostasis: evaluation in GABAB receptor knockout mice. Am J Physiol Endocrinol Metab 2008,294(1),E157-E167","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11062-017-9622-1","volume":"49","author":"Naumenko A.M.","year":"2017","unstructured":"Naumenko A.M.; Shapoval L.M.; Nyporko A.Y.; Voiteshenko M.I.; Tsymbalyuk A.V.; Sagach V.F.; Davydovska T.L.; Computer simulation of molecular interaction between baclofen and the GABAB receptor. Neurophysiol 2017,49(2-7),1-7","journal-title":"Neurophysiol"}],"container-title":["Combinatorial Chemistry & High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/188882","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188882\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/188882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T17:44:05Z","timestamp":1647107045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188882\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207323666201209093240","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}